Jump to Main Content
Development of Nanoscale Oil Bodies for Targeted Treatment of Lung Cancer
- Chiang, Chung-Jen, Lin, Li-Jen, Wu, Chia-Pei, Chen, Chih-Jung, Chao, Yun-Peng
- Journal of agricultural and food chemistry 2018 v.66 no.36 pp. 9438-9445
- Escherichia coli, antineoplastic activity, antineoplastic agents, epidermal growth factor receptors, hydrophobicity, lipid bodies, lung neoplasms, neoplasm cells, oleosin, phospholipids, plant fats and oils, therapeutics
- Lung cancer is the most widespread disease and is frequently associated with a high level of epidermal growth factor receptor (EGFR). This study was thus conducted to provide a proof-of-concept approach for targeted therapy of lung cancer by development of nanoscale oil bodies (NOBs). This was carried out by fusion of anti-EGFR affibody (ZEGFR₂) with oleosin (Ole), a structure protein of plant seed oils. The fusion protein (Ole-ZEGFR₂) was produced in Escherichia coli. NOBs were spontaneously assembled from plant oil, phospholipids, and Ole-ZEGFR₂. Consequently, Ole-ZEGFR₂-based NOBs were selectively internalized by EGFR-positive lung cancer cells with an efficiency exceeding 90%. Furthermore, the hydrophobic anticancer drug, camptothecin (CPT), was encapsulated into Ole-ZEGFR₂-based NOBs. The administration of the CPT formulation based on NOBs resulted in a strong antitumor activity both in vitro and in vivo.